912668-70-3

Basic information

• Product Name: 2H-Indol-2-one, 3-(1,3-benzodioxol-5-yl)-1,3-dihydro-3-hydroxy-1-pentyl-
• CAS NO: 912668-70-3
• Molecular Formula: C20H21NO4
• Molecular Weight: 339.391
• Mol File: 912668-70-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2H-Indol-2-one, 3-(1,3-benzodioxol-5-yl)-1,3-dihydro-3-hydroxy-1-pentyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Indol-2-one, 3-(1,3-benzodioxol-5-yl)-1,3-dihydro-3-hydroxy-1-pentyl-(912668-70-3)
• EPA Substance Registry System: 2H-Indol-2-one, 3-(1,3-benzodioxol-5-yl)-1,3-dihydro-3-hydroxy-1-pentyl-(912668-70-3)

Safety Data

• Hazardous Substances Data: 912668-70-3(Hazardous Substances Data)

Upstream product

• 4290-90-8 1-pentylisatin 
• 17680-04-5 (3,4-methylenedioxy)phenylmagnesium bromide 

Downstream Products

• 1314583-48-6 C₂₈H₂₈N₂O₄ 

Relevant articles and documents

Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain

Starting from the oxindole 2a identified through a high-throughput screening campaign, a series of NaV1.7 blockers were developed. Following the elimination of undesirable structural features, preliminary optimization of the oxindole C-3 and N-1 substituents afforded the simplified analogue 9b, which demonstrated a 10-fold increase in target potency versus the original HTS hit. A scaffold rigidification strategy then led to the discovery of XEN907, a novel spirooxindole NaV1.7 blocker. This lead compound, which in turn showed a further 10-fold increase in potency, represents a promising structure for further optimization efforts.

SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS

This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.